Cancer-Associated Hypercalcemia

被引:45
作者
Guise, Theresa A. [1 ,2 ,3 ]
Wysolmerski, John J. [4 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Sect Bone & Mineral Disorders, Houston, TX 77030 USA
[2] Lawrence Bone Dis Program Texas, Houston, TX 77030 USA
[3] Canc Prevent Res Inst Texas, Austin, TX 78701 USA
[4] Yale Sch Med, Dept Med, Sect Endocrinol & Metab, New Haven, CT USA
关键词
HORMONE-RELATED PROTEIN; MALIGNANCY-ASSOCIATED HYPERCALCEMIA; ZOLEDRONIC ACID; HUMORAL HYPERCALCEMIA; DOUBLE-BLIND; DENOSUMAB; PAMIDRONATE; METASTASES; PREVENTION; EXPERIENCE;
D O I
10.1056/NEJMcp2113128
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 60-year-old woman presents to the emergency department with somnolence and poor appetite. Five months earlier, she received a diagnosis of invasive, high-grade, urothelial carcinoma and underwent four cycles of neoadjuvant chemotherapy, and 1 month earlier, she underwent open radical cystectomy. She has no other significant medical history. The serum calcium level is 16.1 mg per deciliter (4.02 mmol per liter; reference range, 8.8 to 10.2 mg per deciliter [2.2 to 2.5 mmol per liter]); previous serum calcium levels were normal. The albumin level is 4 g per deciliter, blood urea nitrogen 27 mg per deciliter (9.6 mmol per liter), creatinine 1.2 mg per deciliter (106.1 mu mol per liter), and phosphorus 2.1 mg per deciliter (0.7 mmol per liter). The parathyroid hormone (PTH) level is 10 pg per milliliter (reference range, 15 to 65), parathyroid hormone-related protein (PTHrP) 187 pg per milliliter (reference range, 14 to 27), 25-hydroxyvitamin D 28 ng per milliliter (70 nmol per liter; reference range, 20 to 50 ng per milliliter [50 to 125 nmol per liter]), and 1,25-dihydroxyvitamin D 77 pg per milliliter (200 nmol per liter; reference range, 25 to 66 pg per milliliter [65 to 172 nmol per liter]). A whole-body bone scan shows no skeletal metastases. How should this patient be treated?
引用
收藏
页码:1443 / 1451
页数:9
相关论文
共 55 条
  • [1] VITAMIN-D METABOLITE-MEDIATED HYPERCALCEMIA
    ADAMS, JS
    [J]. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1989, 18 (03) : 765 - 778
  • [2] Ionized calcium
    Baird, Geoffrey S.
    [J]. CLINICA CHIMICA ACTA, 2011, 412 (9-10) : 696 - 701
  • [3] Denosumab and bisphosphonates: Different mechanisms of action and effects
    Baron, Roland
    Ferrari, Serge
    Russell, R. Graham G.
    [J]. BONE, 2011, 48 (04) : 677 - 692
  • [4] Outcomes of hypercalcemia of malignancy in patients with solid cancer: a national inpatient analysis
    Bhandari, Shruti
    Kumar, Rohit
    Tripathi, Prashant
    Chan, Abigail
    Mudra, Sarah
    Redman, Rebecca
    [J]. MEDICAL ONCOLOGY, 2019, 36 (10)
  • [5] EFFECT OF CALCITONIN AND GLUCOCORTICOIDS IN COMBINATION ON THE HYPERCALCEMIA OF MALIGNANCY
    BINSTOCK, ML
    MUNDY, GR
    [J]. ANNALS OF INTERNAL MEDICINE, 1980, 93 (02) : 269 - 272
  • [6] HYPERCALCEMIA ASSOCIATED WITH INCREASED SERUM CALCITRIOL LEVELS IN 3 PATIENTS WITH LYMPHOMA
    BRESLAU, NA
    MCGUIRE, JL
    ZERWEKH, JE
    FRENKEL, EP
    PAK, CYC
    [J]. ANNALS OF INTERNAL MEDICINE, 1984, 100 (01) : 1 - 7
  • [7] IMMUNOCHEMICAL CHARACTERIZATION OF CIRCULATING PARATHYROID-HORMONE RELATED PROTEIN IN PATIENTS WITH HUMORAL HYPERCALCEMIA OF CANCER
    BURTIS, WJ
    BRADY, TG
    ORLOFF, JJ
    ERSBAK, JB
    WARRELL, RP
    OLSON, BR
    WU, TL
    MITNICK, ME
    BROADUS, AE
    STEWART, AF
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (16) : 1106 - 1112
  • [8] Calcium free hemodialysis: Experience in the treatment of 33 patients with severe hypercalcemia
    Camus, C
    Charasse, C
    JouannicMontier, I
    Seguin, P
    Tulzo, YL
    Bouget, J
    Thomas, R
    [J]. INTENSIVE CARE MEDICINE, 1996, 22 (02) : 116 - 121
  • [9] Endocrine and metabolic emergencies: hypercalcaemia
    Carroll, Richard
    Matfin, Glenn
    [J]. THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2010, 1 (05) : 225 - 234
  • [10] Zoledronic acid
    Cheer S.M.
    Noble S.
    [J]. Drugs, 2001, 61 (6) : 799 - 805